$125M Zymergen IPO Securities Settlement

Current Status

Claims are open. The deadline to submit a Proof of Claim online or to have a mailed form postmarked is October 11, 2026; the notice states the date without a timezone, so treat the date itself as the cutoff. The court preliminarily approved the settlement and authorized notice to the class, which went out under a court order dated June 22, 2026. The Settlement Hearing on final approval is set for October 13, 2026 at 10:00 a.m. before the U.S. District Court for the Northern District of California in San Jose — two days after the claim deadline. No final approval order has been entered and no payment date has been announced. Payments follow only after the court approves the settlement and a plan of allocation, after any appeals are resolved, and after all claims are processed.

What Is the Case About?

Zymergen was a synthetic-biology company that pitched investors on a "biofacturing" platform it said could make better products faster, cheaper, and more sustainably. It went public in April 2021, selling roughly 18.5 million shares at $31.00 and raising about $575 million.

The lawsuit alleges that the registration statement and prospectus for that offering contained material misstatements and omissions about the biofacturing platform, the development status of eleven products in the company's pipeline, the market opportunity for those products, and when those products would actually generate revenue. According to the complaint, the truth emerged in August and November 2021, when Zymergen announced downward revisions to expected revenue, delays and cancellations in the product pipeline, smaller market opportunities, and departures from management. The stock closed at $8.25 on August 4, 2021 — down from the $31.00 offering price.

The claims are brought under Sections 11 and 15 of the Securities Act of 1933. Section 11 targets the offering documents themselves; Section 15 reaches those alleged to have controlled the entities that issued them. The settling defendants deny all of it. They deny making any materially misleading statement, deny any wrongdoing or violation of law, deny that any class member was harmed or suffered damages, and state that they performed reasonable and customary due diligence on the registration statement. The venture-capital defendants separately argue they did not control Zymergen or the directors they appointed. No court has found any of the allegations true, and the settlement is not an admission of anything.

Who Is Actually Paying — and Who Is Not

This is the detail that makes the case unusual, and it matters if you are wondering why the recovery looks the way it does.

Zymergen itself is not paying. The company filed for Chapter 11 bankruptcy in October 2023. After the Delaware bankruptcy court confirmed its plan of liquidation in February 2024, this case could proceed against Zymergen only to the extent of available insurance — and that insurance has since been fully exhausted. Zymergen asserts it is not subject to liability in the action and is not a party to the settlement. Notably, neither Zymergen nor the ZYM Liquidating Trust is a released party, and the settlement expressly does not release the separate claims in the liquidating trustee's own state-court suit.

The $125,000,000 is instead being paid by the settling defendants: former Zymergen officers and directors, the offering's underwriters — J.P. Morgan Securities, Goldman Sachs, Cowen (now TD Securities), BofA Securities, UBS Securities, and Lazard Frères — and several venture-capital funds and their management companies, including True Ventures, SoftBank Vision Fund entities, and DCVC entities. How the total is split among them is confidential and was not filed publicly.